As this share has grown, however, Novo shareholders should be aware that GLP-1 agonists have become an increasingly large ...

On November 5, the US Food and Drug Administration (FDA) updated the labels for all glucagon-like peptide 1 receptor agonists (GLP-1 RA) with a warning about pulmonary aspiration during general ...

Low-income patients' access to blockbuster weight-loss drugs through Medicaid remains limited, a new KFF analysis has found.

In a multisociety clinical practice guidance document, published online Oct. 29 in Surgery for Obesity and Related Diseases, ...

Only 13 states currently allow Medicaid to cover treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) medications, researchers said.

With the FDA approval of the first specific drug for Metabolic Associated Steatohepatitis (MASH) in March this year, Madrigal’s Rezdiffra is a pioneer in a market set for rapid change. | With the FDA ...

While expected and seen as largely incremental, Jefferies analyst Peter Welford in a Tuesday note to investors said the detailed data for three early-stage assets support moving them into Phase IIb ...

Welcome to the healthier, happier world of 2030. Heart attacks and strokes are down 20%. A drop in food consumption has left ...

The clinical-stage drugmaker is developing an anti-obesity drug that could go on to produce record-breaking sales.

Weight loss from behavioral changes or medication can improve glycemic control and increase menstrual frequency in polycystic ...

Compounded GLP-1s are essentially copies of popular weight loss medications made by manufacturers such as Novo Nordisk and Eli Lilly. Hims & Hers CEO Andrew Dudum said during the company's third ...

But patients taking GLP-1 drugs did have a greater likelihood of retained gastric contents and of aborted upper endoscopies, ...